Alerta De Seguridad para EnTrust VR/DRI AT Implantable Cardioverter Defibrillators

Según Department of Health, este evento ( alerta de seguridad ) involucró a un dispositivo médico en Hong Kong que fue producido por Medtronic.

¿Qué es esto?

Las alertas proporcionan información importante y recomendaciones sobre los productos. Aunque se haya emitido una alerta, esto no significa necesariamente que el producto se considera peligroso. Las alertas de seguridad, dirigidas a trabajadores de la salud y a usuarios, pueden incluir retiro de equipos. Pueden ser escritas por los fabricantes, pero también por funcionarios del área de salud.

Más información acerca de la data acá
  • Tipo de evento
    Safety alert
  • Fecha
  • Fecha de publicación del evento
  • País del evento
  • Fuente del evento
  • URL de la fuente del evento
  • Notas / Alertas
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • Notas adicionales en la data
    Medical Device Safety Alert
  • Causa
    Medical device safety alert: medtronic entrust vr/dri at implantable cardioverter defibrillators medical device manufacturer, medtronic, has issued a medical device safety alert concerning its entrust vr/dri at (icds) [model: d154atg, d154vrc]. the manufacturer has identified of the potential for loss of high voltage and anti-tachycardia pacing therapy in the affected products as they near elective replacement indicator (eri) voltage. according to the manufacturer, under certain circumstances, the device may display an immediate end of life (eol) observation with no prior eri alert. though no eri alert is triggered there may not be enough remaining battery capacity to charge the high voltage circuits, resulting in an excessive charge time eol observation, leading to a loss of high voltage and anti-tachycardia pacing therapy. bradycardia therapies will continue to operate as expected. through 15 jun 2018, the manufacturer has confirmed 25 charge timeout events related to the issue, with no patient deaths or complications. time from implant to the devices experiencing the issue is ranging from 7.9-11.7 years. the affected users are recommended to take the following actions: consider scheduling an in-office patient follow-up as soon as possible to assess the potential for the issue. ensure the “excessive charge time eol...And the low battery voltage eri ...” patient alerts have been programmed to "on-high" instruct patients to contact manufacturer if they hear device alert tones. consider utilizing the "demonstrate tones...” function to ensure patients recognize the audible tone. if the issue has occurred, an "eol: replace device immediately" observation will be displayed on the quicklook report. schedule a device replacement immediately. additionally, the manufacturer recommends the actions to help ensure patient safety and effective high voltage therapy remain as the device battery voltage approaches its 2.61v eri threshold the manufacturer will offer a supplemental device warranty for prophylactic replacements as defined under the patient management recommendations. according to the local supplier, the affected products are distributed in hong kong. if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 28 june 2018.


  • Modelo / Serial
  • Descripción del producto
    Medical Device Safety Alert: Medtronic EnTrust VR/DRI AT Implantable Cardioverter Defibrillators
  • Manufacturer


  • Empresa matriz del fabricante (2017)
  • Comentario del fabricante
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source